Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Kath Kerry

- PMLiVE

Pfizer doses first patient in investigational haemophilia drug trial

Company is evaluating marstacimab in severe haemophilia A/B patients

- PMLiVE

WHO director-general says urgent support is needed for COVAX facility

Immediate funding support totalling $4.3bn is required

- PMLiVE

FDA sets 10 December date for Pfizer’s COVID-19 vaccine meeting

Independent experts will discuss EUA submission for mRNA-based vaccine

- PMLiVE

Rethinking our approach to infectious disease preparedness

The importance of long-term strategic investment to prepare for the next threat that emerges

- PMLiVE

Lilly links up with Precision BioSciences in genome editing deal

Precision will receive an upfront cash payment of $100m

- PMLiVE

Laurence Bannister joins Lucid Group as its new Chief Commercial Officer

Laurence brings a track record of success from 22 years’ experience in pharmaceuticals/healthcare – across affiliate, regional and global commercial roles – with the last 9 years being at STEM...

Lucid Group Communications Limited

- PMLiVE

UK could approve Pfizer’s COVID-19 vaccine this week

The Telegraph reported the possible timeframe on Sunday

regeneron headquarters

Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval

Drug approved to treat high-risk patients with mild to moderate COVID-19

- PMLiVE

AZ’s COVID-19 vaccine demonstrates efficacy rate of up to 90%

Across two dosing regimens, vaccine has average efficacy of 70%

- PMLiVE

Power to the patient: digital innovation supporting patients with chronic diseases

By Abby Purdy

- PMLiVE

Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval

Drug approved for emergency use in combination with Gilead's remdesivir

- PMLiVE

Building a brighter future for rare disease patients

By Malcolm Barratt-Johnson

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links